Quantum-Si Inc — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Quantum-Si announced interim development results for its next-generation Proteus protein sequencing platform (in development, targeting Q2 2027 launch). In control peptide studies, Proteus delivered 30× more alignments per single chamber (median 4.09M vs 135.9k), 4.8× lower false discovery rate (1.36% vs 6.58%), and identified all 6 control peptides in every run vs. variable success on Platinum Pro. In 24-protein mixture tests, Proteus detected 4.3× more amino acids (269,864 vs 63,366), identified all 24 proteins vs. average 20.3 on Platinum, and detected 1.6–2.0× more peptides. Proteus uses 80M nanowell array vs Platinum's 2M wells; still uses developmental 18-amino-acid detection kit, with goal to detect all 20 AAs by end of 2026.
Why this rating
Interim data supports Proteus as transformational next-gen product; 30–60× performance gains justify capital investment. Risk: still pre-launch, unoptimized, and regulatory/commercialization hurdles remain. Material but not certain.
Price action (we called it positive)
before filing · preread $0.83 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.